VivoSeq
Psychiatry

Alcohol Use Disorder

11

Pipeline Programs↗

65

Active Trials↗

12

Companies Involved↗

Alcohol Use Disorder is an emerging landscape with 11 programs across 12 companies. The most active players are Pfizer, Imbrium Therapeutics, Knoa Pharma LLC. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

54/100

Mech. Concentration

25/100

Completion Rate

77/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1I

Imbrium Therapeutics

1 program

Phase 2K

Knoa Pharma LLC

1 program

Phase 2A

Azurity Pharmaceuticals

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Teva logo

Teva

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSPeptide113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 67% of 12 pipeline programs.

Analysis

Trial Status

119

clinical trials

Completed41 · 34%
Recruiting37 · 31%
Not yet recruiting16 · 13%
Active, not recruiting11 · 9%
Withdrawn6 · 5%
Terminated5 · 4%
Other3 · 3%

Clinical Trials

Trial Activity

119 trials

Emergency Department-Initiated Medications for Alcohol Use Disorder
Recruiting·YYale University·Phase 3·NCT05827159·240 enrolled
Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder
Recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT06512389·36 enrolled
Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat
Recruiting·YYale University·N/A·NCT06371404·150 enrolled
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
Recruiting·YYale University·Phase 2·NCT07040592·30 enrolled
Tirzepatide for Alcohol Use Disorder
Recruiting·UUniversity of Southern California·Phase 2·NCT06994338·42 enrolled
Cannabidiol for Reducing Drinking in Alcohol Use Disorder
Recruiting·HHôpital le Vinatier·Phase 2·NCT05159830·76 enrolled
Citicoline in Youth Alcohol Use Disorder
Recruiting·MMedical University of South Carolina·Phase 2·NCT05870111·56 enrolled
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
Recruiting·OOhio State University·Phase 2·NCT07214207·250 enrolled
Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder
Recruiting·National Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 4·NCT06269627·48 enrolled
PT150 Drug for Use in Alcohol Use Disorder
Recruiting·PPop Test Oncology LLC·Phase 1·NCT06712602·34 enrolled
ACT_for Alcohol Use Disorder and Depression
Recruiting·—·N/A·NCT06620276·30 enrolled
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD
Recruiting·NNYU Langone Health·Phase 2·NCT03667846·150 enrolled
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1
Recruiting·YYale University·Phase 2·NCT06004830·30 enrolled
Brexpiprazole in Alcohol Use Disorder
Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04066192·250 enrolled
Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
Recruiting·YYale University·Phase 2·NCT04793685·150 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)